INTEGRA LIFESCIENCES HOLDING (IART)
US4579852082 - Common Stock
Overall IART gets a fundamental rating of 4 out of 10. We evaluated IART against 187 industry peers in the Health Care Equipment & Supplies industry. IART has a medium profitability rating, but doesn't score so well on its financial health evaluation. IART has a bad growth rate and is valued cheaply.
1. Profitability
1.1 Basic Checks
In the past year IART was profitable.
IART had a positive operating cash flow in the past year.
In the past 5 years IART has always been profitable.
IART had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
IART has a better Return On Assets (-0.16%) than 69.52% of its industry peers.
The Return On Equity of IART (-0.43%) is better than 70.59% of its industry peers.
IART has a Return On Invested Capital of 4.93%. This is in the better half of the industry: IART outperforms 77.54% of its industry peers.
IART had an Average Return On Invested Capital over the past 3 years of 6.75%. This is in line with the industry average of 8.19%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.16% | ||
| ROE | -0.43% | ||
| ROIC | 4.93% |
ROA(3y)3.63%
ROA(5y)3.23%
ROE(3y)8.1%
ROE(5y)7.34%
ROIC(3y)6.75%
ROIC(5y)6.66%
1.3 Margins
IART's Profit Margin has been stable in the last couple of years.
With an excellent Operating Margin value of 11.84%, IART belongs to the best of the industry, outperforming 80.21% of the companies in the same industry.
In the last couple of years the Operating Margin of IART has grown nicely.
IART has a Gross Margin (59.29%) which is in line with its industry peers.
IART's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 11.84% | ||
| PM (TTM) | N/A | ||
| GM | 59.29% |
OM growth 3Y3.4%
OM growth 5Y2.16%
PM growth 3Y-23.36%
PM growth 5Y1.25%
GM growth 3Y-0.76%
GM growth 5Y-0.14%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), IART is destroying value.
The number of shares outstanding for IART has been reduced compared to 1 year ago.
IART has less shares outstanding than it did 5 years ago.
Compared to 1 year ago, IART has a worse debt to assets ratio.
2.2 Solvency
IART has an Altman-Z score of 1.30. This is a bad value and indicates that IART is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of 1.30, IART is in line with its industry, outperforming 50.80% of the companies in the same industry.
IART has a debt to FCF ratio of 47.52. This is a negative value and a sign of low solvency as IART would need 47.52 years to pay back of all of its debts.
Looking at the Debt to FCF ratio, with a value of 47.52, IART is in the better half of the industry, outperforming 67.38% of the companies in the same industry.
IART has a Debt/Equity ratio of 0.79. This is a neutral value indicating IART is somewhat dependend on debt financing.
IART has a Debt to Equity ratio of 0.79. This is in the lower half of the industry: IART underperforms 74.87% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.79 | ||
| Debt/FCF | 47.52 | ||
| Altman-Z | 1.3 |
ROIC/WACC0.63
WACC7.79%
2.3 Liquidity
IART has a Current Ratio of 1.20. This is a normal value and indicates that IART is financially healthy and should not expect problems in meeting its short term obligations.
The Current ratio of IART (1.20) is worse than 86.63% of its industry peers.
IART has a Quick Ratio of 1.20. This is a bad value and indicates that IART is not financially healthy enough and could expect problems in meeting its short term obligations.
IART has a Quick ratio of 0.73. This is amonst the worse of the industry: IART underperforms 90.91% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.2 | ||
| Quick Ratio | 0.73 |
3. Growth
3.1 Past
The earnings per share for IART have decreased strongly by -21.27% in the last year.
The Earnings Per Share has been growing slightly by 5.08% on average over the past years.
The Revenue has been growing slightly by 1.45% in the past year.
IART shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 0.92% yearly.
EPS 1Y (TTM)-21.27%
EPS 3Y8.16%
EPS 5Y5.08%
EPS Q2Q%-46.05%
Revenue 1Y (TTM)1.45%
Revenue growth 3Y3.96%
Revenue growth 5Y0.92%
Sales Q2Q%-0.93%
3.2 Future
The Earnings Per Share is expected to grow by 2.69% on average over the next years.
IART is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 5.90% yearly.
EPS Next Y-19.35%
EPS Next 2Y-9.05%
EPS Next 3Y-2.93%
EPS Next 5Y2.69%
Revenue Next Year4.44%
Revenue Next 2Y5.32%
Revenue Next 3Y5%
Revenue Next 5Y5.9%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 8.79, which indicates a very decent valuation of IART.
97.86% of the companies in the same industry are more expensive than IART, based on the Price/Earnings ratio.
Compared to an average S&P500 Price/Earnings ratio of 27.73, IART is valued rather cheaply.
IART is valuated reasonably with a Price/Forward Earnings ratio of 8.50.
98.40% of the companies in the same industry are more expensive than IART, based on the Price/Forward Earnings ratio.
Compared to an average S&P500 Price/Forward Earnings ratio of 22.83, IART is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 8.79 | ||
| Fwd PE | 8.5 |
4.2 Price Multiples
IART's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. IART is cheaper than 94.12% of the companies in the same industry.
IART's Price/Free Cash Flow ratio is a bit cheaper when compared to the industry. IART is cheaper than 77.01% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 44.25 | ||
| EV/EBITDA | 9.85 |
4.3 Compensation for Growth
IART has a very decent profitability rating, which may justify a higher PE ratio.
A cheap valuation may be justified as IART's earnings are expected to decrease with -2.93% in the coming years.
PEG (NY)N/A
PEG (5Y)1.73
EPS Next 2Y-9.05%
EPS Next 3Y-2.93%
5. Dividend
5.1 Amount
IART does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
INTEGRA LIFESCIENCES HOLDING
NASDAQ:IART (12/20/2024, 8:17:35 PM)
After market: 21.8 0 (0%)21.8
+0.09 (+0.41%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners95.17%
Inst Owner Change6.18%
Ins Owners3.12%
Ins Owner Change0.05%
Market Cap1.68B
Analysts53.68
Price Target28.67 (31.51%)
Short Float %4.56%
Short Ratio3.97
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)1.22%
Min EPS beat(2)-0.79%
Max EPS beat(2)3.22%
EPS beat(4)1
Avg EPS beat(4)-0.8%
Min EPS beat(4)-3.39%
Max EPS beat(4)3.22%
EPS beat(8)3
Avg EPS beat(8)1.92%
EPS beat(12)5
Avg EPS beat(12)3.13%
EPS beat(16)9
Avg EPS beat(16)6.5%
Revenue beat(2)0
Avg Revenue beat(2)-0.71%
Min Revenue beat(2)-0.77%
Max Revenue beat(2)-0.64%
Revenue beat(4)0
Avg Revenue beat(4)-1.01%
Min Revenue beat(4)-2.52%
Max Revenue beat(4)-0.09%
Revenue beat(8)1
Avg Revenue beat(8)-1.08%
Revenue beat(12)2
Avg Revenue beat(12)-0.8%
Revenue beat(16)4
Avg Revenue beat(16)-0.65%
PT rev (1m)4.6%
PT rev (3m)-0.39%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-14.78%
EPS NY rev (1m)0.22%
EPS NY rev (3m)0.07%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-2.44%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 8.79 | ||
| Fwd PE | 8.5 | ||
| P/S | 1.07 | ||
| P/FCF | 44.25 | ||
| P/OCF | 12.24 | ||
| P/B | 1.11 | ||
| P/tB | N/A | ||
| EV/EBITDA | 9.85 |
EPS(TTM)2.48
EY11.38%
EPS(NY)2.56
Fwd EY11.76%
FCF(TTM)0.49
FCFY2.26%
OCF(TTM)1.78
OCFY8.17%
SpS20.28
BVpS19.72
TBVpS-10.43
PEG (NY)N/A
PEG (5Y)1.73
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.16% | ||
| ROE | -0.43% | ||
| ROCE | 5.87% | ||
| ROIC | 4.93% | ||
| ROICexc | 5.41% | ||
| ROICexgc | 28.31% | ||
| OM | 11.84% | ||
| PM (TTM) | N/A | ||
| GM | 59.29% | ||
| FCFM | 2.43% |
ROA(3y)3.63%
ROA(5y)3.23%
ROE(3y)8.1%
ROE(5y)7.34%
ROIC(3y)6.75%
ROIC(5y)6.66%
ROICexc(3y)7.7%
ROICexc(5y)7.53%
ROICexgc(3y)26.08%
ROICexgc(5y)25.66%
ROCE(3y)8.04%
ROCE(5y)7.93%
ROICexcg growth 3Y-0.69%
ROICexcg growth 5Y-4.78%
ROICexc growth 3Y2.49%
ROICexc growth 5Y-0.08%
OM growth 3Y3.4%
OM growth 5Y2.16%
PM growth 3Y-23.36%
PM growth 5Y1.25%
GM growth 3Y-0.76%
GM growth 5Y-0.14%
F-Score4
Asset Turnover0.38
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.79 | ||
| Debt/FCF | 47.52 | ||
| Debt/EBITDA | 3.77 | ||
| Cap/Depr | 73.99% | ||
| Cap/Sales | 6.35% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 42.99% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.2 | ||
| Quick Ratio | 0.73 | ||
| Altman-Z | 1.3 |
F-Score4
WACC7.79%
ROIC/WACC0.63
Cap/Depr(3y)44.7%
Cap/Depr(5y)62.4%
Cap/Sales(3y)3.49%
Cap/Sales(5y)4.8%
Profit Quality(3y)128.19%
Profit Quality(5y)136.42%
High Growth Momentum
Growth
EPS 1Y (TTM)-21.27%
EPS 3Y8.16%
EPS 5Y5.08%
EPS Q2Q%-46.05%
EPS Next Y-19.35%
EPS Next 2Y-9.05%
EPS Next 3Y-2.93%
EPS Next 5Y2.69%
Revenue 1Y (TTM)1.45%
Revenue growth 3Y3.96%
Revenue growth 5Y0.92%
Sales Q2Q%-0.93%
Revenue Next Year4.44%
Revenue Next 2Y5.32%
Revenue Next 3Y5%
Revenue Next 5Y5.9%
EBIT growth 1Y-34.31%
EBIT growth 3Y7.5%
EBIT growth 5Y3.1%
EBIT Next Year-0.86%
EBIT Next 3Y4.01%
EBIT Next 5YN/A
FCF growth 1Y-79.8%
FCF growth 3Y-19.46%
FCF growth 5Y-9.74%
OCF growth 1Y-44.66%
OCF growth 3Y-11.77%
OCF growth 5Y-6.86%